PRESS RELEASE: Carina to present at 7th annual Cell and Gene Therapy World Asia 2023 Conference
ADELAIDE, AUSTRALIA, September 13, 2023 Carina Biotech (Carina) invited to present at 7th annual Cell and Gene Therapy World Asia
PRESS RELEASE: Carina Biotech to Present Preclinical Data at 8th CAR-TCR Summit
ADELAIDE, AUSTRALIA, August 21, 2023 Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Human Cancer Models
PRESS RELEASE: Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, AUSTRALIA, June 5, 2023 Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S.
PRESS RELEASE: Carina Biotech to Participate in Three Upcoming Conferences
ADELAIDE, AUSTRALIA, May 25, 2023 Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will participate in the three
PRESS RELEASE: Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial at 2023 ASCO Annual Meeting
ADELAIDE, AUSTRALIA, April 2, 2023 Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell
PRESS RELEASE: Carina to present at AACR 2023
ADELAIDE, AUSTRALIA, March 22, 2023 Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Colorectal Cancer Models
PRESS RELEASE: Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models
PRESS RELEASE, February 7, 2023 Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T
Carina receives ‘Safe to proceed’ letter for Phase 1/2a clinical trial of CNA3103
PRESS RELEASE Tuesday, January 24, 2023 Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a